CsDCS on Functional Mobility in Parkinsons Disease
Parkinsons disease is a progressive neurological disorder marked by a decline in the efficacy of dopaminergic synapses in the nigrostriatal pathway, causing motor disturbances. Resting tremor, bradykinesia, and muscle rigidity are the most prominent motor features. These factors result in gait impairments, including sl
| Condition(s) | Parkinson Disease |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Parkinsons disease is a progressive neurological disorder marked by a decline in the efficacy of dopaminergic synapses in the nigrostriatal pathway, causing motor disturbances. Resting tremor, bradykinesia, and muscle rigidity are the most prominent motor features. These factors result in gait impairments, including slowness and freezing. The primary treatment for the disease is medication. However, while medication does reduce motor symptoms, prolonged usage may lead to an increase of dyskinesias and a worsening of a patients clinical condition. Thus, alternative therapies, such as cerebellospinal direct current stimulation (csDCS), have gained popularity. Studies suggest that csDCS may be an effective approach to mitigate gait disorders in this patient population. Kinesiotherapy is an es |
| Who can participate | Inclusion Criteria: * a clinical diagnosis of PD provided by a neurologist * regular dopaminergic drug treatment (at least three months of use) * aged 40 years or over * staging I to IV on the modified Hoehn and Yahr scale Exclusion Criteria: * other neurological disorders, postural hypotension, vestibular, musculoskeletal or visual disorders that compromise performance in the proposed tests * other osteoarticular diseases in the lower limbs that interfere with performance and locomotion * a Montreal Cognitive Assessment (MoCA) score of less than 21 points * have undergone previous surgery for PD |
| Ages | 40 Years |
| Sex | All |
| Lead sponsor | Universidade Federal de Pernambuco |
| Locations | Recife, Pernambuco, Brazil |
| Start date | 2024-05-09 |
| NCT ID | NCT06856941 |
| Official listing | https://clinicaltrials.gov/study/NCT06856941 |